Mechanistic analysis of actin-binding compounds that affect the kinetics of cardiac myosin–actin interaction

Abstract

Actin–myosin mediated contractile forces are crucial for many cellular functions, including cell motility, cytokinesis, and muscle contraction. We determined the effects of ten actin-binding compounds on the interaction of cardiac myosin subfragment 1 (S1) with pyrene-labeled F-actin (PFA). These compounds, previously identified from a small-molecule high-throughput screen (HTS), perturb the structural dynamics of actin and the steady-state actin-activated myosin ATPase activity. However, the mechanisms underpinning these perturbations remain unclear. Here we further characterize them by measuring their effects on PFA fluorescence, which is decreased specifically by the strong binding of myosin to actin. We measured these effects under equilibrium and steady-state conditions, and under transient conditions, in stopped-flow experiments following addition of ATP to S1-bound PFA. We observed that these compounds affect early steps of the myosin ATPase cycle to different extents. They increased the association equilibrium constant K 1 for the formation of the strongly bound collision complex, indicating increased ATP affinity for actin-bound myosin, and decreased the rate constant k + 2 for subsequent isomerization to the weakly bound ternary complex, thus slowing the strong-to-weak transition that actin–myosin interaction undergoes early in the ATPase cycle. The compounds' effects on actin structure allosterically inhibit the kinetics of the actin–myosin interaction in ways that may be desirable for treatment of hypercontractile forms of cardiomyopathy. This work helps to elucidate the mechanisms of action for these compounds, several of which are currently used therapeutically, and sets the stage for future HTS campaigns that aim to discover new drugs for treatment of heart failure.

From the Matrix to the Nucleus and Back: Mechanobiology in the Light of Health, Pathologies, and Regeneration of Oral Periodontal Tissues

“…G-actin binds adenosine-triphosphate (ATP) and hydrolyses ATP to adenosinediphosphate (ADP) within F-actin. This reaction goes along with conformational changes of actin monomers and contributes to the dynamic turnover of actin-related cytoskeletal structures [67][68][69]. Actin polymerization is regulated by a class of guanosine-triphosphate (GTP) binding proteins, known as Ras homologue A (RhoA), cell division control protein homolog 42 (Cdc42), Ras-related C3 botulinum toxin substrate 1 (Rac1), as well as the Rho-associated, coiled-coil-containing protein kinase 1 (ROCK1) (Figure 1A) [70][71][72][73].…”

Using hiPSC‐CMs to Examine Mechanisms of Catecholaminergic Polymorphic Ventricular Tachycardia

“…Mavacamten (MYK‐461, Selleckchem, S8861) has been shown to eliminate motion artifacts caused by spontaneous contractions of the hiPSC‐CM monolayer. MYK‐461 primarily reduces the steady‐state myosin ATPase activity and inhibits the rate of phosphate release of β‐cardiac myosin‐S1 heads (Kawas et al., 2017; Psaras et al., 2021; Roopnarine & Thomas, 2021). Our unpublished data suggests that 5 μM Mavacamten is effective at suppressing spontaneous contractions of a hiPSC‐CM monolayer during optical mapping assays.…”

Talin-drug interaction reveals a key molecular determinant for biphasic mechanical effect: studied under single-molecule resolution

“…Mechanosensitive adhesion proteins are structurally predominated by α-helix folds, which acts as a critical determinant of their forced unfolding and mechanical stability: myosin II, which mediates FA maturation under force, are inhibited by N-benzyl-p-toluene sulphonamide within micromolar concentration range. Similarly, F-actin has been observed to interact with various drugs including flutamide, carvedilol and mitoxantrone 7–9 . Recently, cytochalasin-D and vinblastine as cytoskeletal drugs regulate off-target folding stability of other protein in cells 10 .…”